NCT04816123View on ClinicalTrials.gov

The Mass Balance and Biotransformation of [14C]Donafenib in Healthy Adult Man

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

October 9, 2018

Primary Completion Date

December 18, 2018

Study Completion Date

December 18, 2018

Conditions
Healthy Male Adult
Interventions
DRUG

[14C]Donafenib

Each volunteers received a single 300 mg dose of \[14C\]donafenib (toluene sulfonic acid) containing a radioactivity dose of 120 μCi as an oral suspension, in fasting within 5 minutes.

Trial Locations (1)

215006

The First Affiliated Hospital of Suzhou University, Suzhou

All Listed Sponsors
lead

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

INDUSTRY

NCT04816123 - The Mass Balance and Biotransformation of [14C]Donafenib in Healthy Adult Man | Biotech Hunter | Biotech Hunter